Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking

Trial Profile

Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking

Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2018

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Alcoholism; HIV infections
  • Focus Therapeutic Use
  • Acronyms INSPIRE
  • Most Recent Events

    • 16 May 2018 Primary endpoint (Percentage of Those Maintain or Improve to HIV RNA-1 Viral Load Less Then 200 copies/mL-naltrexone versus placebo) has been met, according to results published in the JAIDS:Journal of Acquired Immune Deficiency Syndromes.
    • 16 May 2018 According to results published in the JAIDS:Journal of Acquired Immune Deficiency Syndromes, definition of one of the primary outcomes changed with respect to number of copies from <400 copies/mL to <200 copies/mL as the Department of Health and Human Services HIV treatment guidelines changed their definition of VS to <200 copies/mL as the goal of therapy soon after study initiation.
    • 16 May 2018 Results published in the JAIDS:Journal of Acquired Immune Deficiency Syndromes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top